Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.

The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers. Whereas some of the established oral hypoglycaemic drug classes li...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Martin C S Wong, Harry H X Wang, Mandy W M Kwan, Daisy D X Zhang, Kirin Q L Liu, Sky W M Chan, Carmen K M Fan, Brian C Y Fong, Shannon T S Li, Sian M Griffiths
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a7e419d61fe44689850eb1782c02cb80
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a7e419d61fe44689850eb1782c02cb80
record_format	dspace
spelling	oai:doaj.org-article:a7e419d61fe44689850eb1782c02cb802021-11-18T08:28:54ZComparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.1932-620310.1371/journal.pone.0090963https://doaj.org/article/a7e419d61fe44689850eb1782c02cb802014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24614606/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers. Whereas some of the established oral hypoglycaemic drug classes like biguanide, sulphonylureas, thiazolidinediones have been extensively used, the newer agents like dipeptidyl peptidase-4 (DPP-4) inhibitors and the human glucagon-like peptide-1 (GLP-1) analogues have recently emerged as suitable options due to their similar efficacy and favorable side effect profiles. These agents are widely recognized alternatives to the traditional oral hypoglycaemic agents or insulin, especially in conditions where they are contraindicated or unacceptable to patients. Many studies which evaluated their clinical effects, either alone or as add-on agents, were conducted in Western countries. There exist few reviews on their effectiveness in the Asia-Pacific region. The purpose of this systematic review is to address the comparative effectiveness of these new classes of medications as add-on therapies to sulphonylurea drugs among diabetic patients in the Asia-Pacific countries. We conducted a thorough literature search of the MEDLINE and EMBASE from the inception of these databases to August 2013, supplemented by an additional manual search using reference lists from research studies, meta-analyses and review articles as retrieved by the electronic databases. A total of nine randomized controlled trials were identified and described in this article. It was found that DPP-4 inhibitors and GLP-1 analogues were in general effective as add-on therapies to existing sulphonylurea therapies, achieving HbA1c reductions by a magnitude of 0.59-0.90% and 0.77-1.62%, respectively. Few adverse events including hypoglycaemic attacks were reported. Therefore, these two new drug classes represent novel therapies with great potential to be major therapeutic options. Future larger-scale research should be conducted among other Asia-Pacific region to evaluate their efficacy in other ethnic groups.Martin C S WongHarry H X WangMandy W M KwanDaisy D X ZhangKirin Q L LiuSky W M ChanCarmen K M FanBrian C Y FongShannon T S LiSian M GriffithsPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 3, p e90963 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Martin C S Wong Harry H X Wang Mandy W M Kwan Daisy D X Zhang Kirin Q L Liu Sky W M Chan Carmen K M Fan Brian C Y Fong Shannon T S Li Sian M Griffiths Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.
description	The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers. Whereas some of the established oral hypoglycaemic drug classes like biguanide, sulphonylureas, thiazolidinediones have been extensively used, the newer agents like dipeptidyl peptidase-4 (DPP-4) inhibitors and the human glucagon-like peptide-1 (GLP-1) analogues have recently emerged as suitable options due to their similar efficacy and favorable side effect profiles. These agents are widely recognized alternatives to the traditional oral hypoglycaemic agents or insulin, especially in conditions where they are contraindicated or unacceptable to patients. Many studies which evaluated their clinical effects, either alone or as add-on agents, were conducted in Western countries. There exist few reviews on their effectiveness in the Asia-Pacific region. The purpose of this systematic review is to address the comparative effectiveness of these new classes of medications as add-on therapies to sulphonylurea drugs among diabetic patients in the Asia-Pacific countries. We conducted a thorough literature search of the MEDLINE and EMBASE from the inception of these databases to August 2013, supplemented by an additional manual search using reference lists from research studies, meta-analyses and review articles as retrieved by the electronic databases. A total of nine randomized controlled trials were identified and described in this article. It was found that DPP-4 inhibitors and GLP-1 analogues were in general effective as add-on therapies to existing sulphonylurea therapies, achieving HbA1c reductions by a magnitude of 0.59-0.90% and 0.77-1.62%, respectively. Few adverse events including hypoglycaemic attacks were reported. Therefore, these two new drug classes represent novel therapies with great potential to be major therapeutic options. Future larger-scale research should be conducted among other Asia-Pacific region to evaluate their efficacy in other ethnic groups.
format	article
author	Martin C S Wong Harry H X Wang Mandy W M Kwan Daisy D X Zhang Kirin Q L Liu Sky W M Chan Carmen K M Fan Brian C Y Fong Shannon T S Li Sian M Griffiths
author_facet	Martin C S Wong Harry H X Wang Mandy W M Kwan Daisy D X Zhang Kirin Q L Liu Sky W M Chan Carmen K M Fan Brian C Y Fong Shannon T S Li Sian M Griffiths
author_sort	Martin C S Wong
title	Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.
title_short	Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.
title_full	Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.
title_fullStr	Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.
title_full_unstemmed	Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.
title_sort	comparative effectiveness of dipeptidyl peptidase-4 (dpp-4) inhibitors and human glucagon-like peptide-1 (glp-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the asia-pacific region: a systematic review.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/a7e419d61fe44689850eb1782c02cb80
work_keys_str_mv	AT martincswong comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview AT harryhxwang comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview AT mandywmkwan comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview AT daisydxzhang comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview AT kirinqlliu comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview AT skywmchan comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview AT carmenkmfan comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview AT briancyfong comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview AT shannontsli comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview AT sianmgriffiths comparativeeffectivenessofdipeptidylpeptidase4dpp4inhibitorsandhumanglucagonlikepeptide1glp1analogueasaddontherapiestosulphonylureaamongdiabetespatientsintheasiapacificregionasystematicreview
_version_	1718421760038141952

Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.

Ejemplares similares